Meeting Banner
Abstract #1541

Regression of Glioma Tumor Growth in a F98 Rat Glioma Model by the Nitrone, OKN-007

Rheal A. Towner1, David L. Gillespie2, Debra Saunders1, Osama Abdullah3, Edward W. Hsu4, Andrea Schwager5, Randy L. Jensen2

1Advanced Magnetic Resonance Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States; 2Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States; 3Bioengineering, University of Utah, Salt Lake City, UT; 4Bioengineering, University of Utah, Salt Lake City, UT, United States; 5Interdepartmental Program in Neuroscience, University of Utah, Salt Lake City, UT, United States

Magnetic resonance imaging and spectroscopy was used to follow the regression of rat F98 gliomas following treatment with the nitrone compound, OKN-007. Following MR and bioluminescence image detection of F98 gliomas, OKN-007 (administered orally) was found to decrease tumor growth. MR spectroscopy analysis (metabolite/tCr (total creatine) peak area ratios, and LCModel) indicated F98 glioma-induced alterations in tumor metabolites (tCho (total choline), tCr, NAA (N-acetyl aspartate), Lip1.3 (methylene hydrogens in lipid acyl groups), Lip5.3 (olefinic hydrogens in unsaturated lipid acyl groups)), were found to revert back to normal levels following OKN-007 treatment. OKN-007 may be considered as a promising therapeutic addition or alternative for the treatment of human gliomas.